M Nauck

Summary

Affiliation: Diabeteszentrum Bad Lauterberg
Country: Germany

Publications

  1. ncbi request reprint Postoperative oral glucose tolerance and stimulated insulin secretion: a predictor of endocrine graft function more than 10 years after pancreas-kidney transplantation
    Frank Pfeffer
    Department of General Surgery, University of Freiburg, Freiburg, Germany
    Transplantation 76:1427-31. 2003
  2. ncbi request reprint Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects
    Juris J Meier
    Department of Medicine, St Josef Hospiital, Ruhr University Bochum, Bochum, Germany
    Diabetes 53:S220-4. 2004
  3. ncbi request reprint Glucagon-like peptide 1 and its derivatives in the treatment of diabetes
    Michael A Nauck
    Diabeteszentrum Bad Lauterberg Kirchberg 21 D 37431 Bad Lauterberg im Harz, Germany
    Regul Pept 128:135-48. 2005
  4. ncbi request reprint Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls
    Juris J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University of Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    World J Gastroenterol 12:1874-80. 2006
  5. ncbi request reprint Incretins and the development of type 2 diabetes
    Juris J Meier
    Curr Diab Rep 6:194-201. 2006
  6. doi request reprint [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin]
    M Nauck
    Diabeteszentrum, Bad Lauterberg, Deutschland
    Dtsch Med Wochenschr 138:S6-15. 2013
  7. ncbi request reprint Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes
    M A Nauck
    Diabeteszentrum Bad Lauterberg, 37431 Bad Lauterberg im Harz, Germany
    Horm Metab Res 36:852-8. 2004
  8. ncbi request reprint Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung
    Michael A Nauck
    Diabeteszentrum Bad Lauterberg, Kirchberg 21, D 37431 Bad Lauterberg im Harz, Germany
    J Clin Endocrinol Metab 92:1600-5. 2007
  9. ncbi request reprint Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1
    Michael A Nauck
    Medizinische Klinik 1, St Josef Hospital, Klinikum der Ruhr Universitat Bochum, Gudrunstr 56, D 44791 Bochum, Germany
    Regul Pept 118:89-97. 2004
  10. ncbi request reprint Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes
    M A Nauck
    Diabeteszentrum, Bad Lauterberg im Harz, Germany
    Exp Clin Endocrinol Diabetes 114:417-23. 2006

Collaborators

Detail Information

Publications61

  1. ncbi request reprint Postoperative oral glucose tolerance and stimulated insulin secretion: a predictor of endocrine graft function more than 10 years after pancreas-kidney transplantation
    Frank Pfeffer
    Department of General Surgery, University of Freiburg, Freiburg, Germany
    Transplantation 76:1427-31. 2003
    ..The authors evaluated the predictive value of postoperative oral glucose tolerance test (OGTT) and stimulated insulin secretion on long-term endocrine function...
  2. ncbi request reprint Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects
    Juris J Meier
    Department of Medicine, St Josef Hospiital, Ruhr University Bochum, Bochum, Germany
    Diabetes 53:S220-4. 2004
    ..Therefore, the existence of a specific GIP receptor defect in type 2 diabetes appears unlikely...
  3. ncbi request reprint Glucagon-like peptide 1 and its derivatives in the treatment of diabetes
    Michael A Nauck
    Diabeteszentrum Bad Lauterberg Kirchberg 21 D 37431 Bad Lauterberg im Harz, Germany
    Regul Pept 128:135-48. 2005
    ..It is hoped that this new class of drugs interacting with the GLP-1 or other incretin receptors, the so-called "incretin mimetics", will broaden our armamentarium of antidiabetic medications in the nearest future...
  4. ncbi request reprint Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls
    Juris J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University of Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    World J Gastroenterol 12:1874-80. 2006
    ..While animal experiments suggested a role for GIP as an inhibitor of gastric secretion, the GIP effects on gastric acid output in humans are still controversial...
  5. ncbi request reprint Incretins and the development of type 2 diabetes
    Juris J Meier
    Curr Diab Rep 6:194-201. 2006
    ..Therefore, although there are hints of early abnormalities in incretin secretion and action in prediabetic populations, it has not been proven that such phenomena are central to the pathogenesis of type 2 diabetes...
  6. doi request reprint [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin]
    M Nauck
    Diabeteszentrum, Bad Lauterberg, Deutschland
    Dtsch Med Wochenschr 138:S6-15. 2013
    ..We compared the efficacy, safety, and tolerability of dapagliflozin with the sulfonylurea glipizide in patients with type 2 diabetes inadequately controlled with metformin monotherapy...
  7. ncbi request reprint Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes
    M A Nauck
    Diabeteszentrum Bad Lauterberg, 37431 Bad Lauterberg im Harz, Germany
    Horm Metab Res 36:852-8. 2004
    ..For more long-term metabolic control, incretin mimetics (agonists at the GLP-1 receptor) with more favourable pharmacokinetic profiles should be used...
  8. ncbi request reprint Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung
    Michael A Nauck
    Diabeteszentrum Bad Lauterberg, Kirchberg 21, D 37431 Bad Lauterberg im Harz, Germany
    J Clin Endocrinol Metab 92:1600-5. 2007
    ..Multiple small lung nodules were detected by computed tomography scan. An undifferentiated large-cell carcinoma was diagnosed from an axillary lymph node metastasis...
  9. ncbi request reprint Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1
    Michael A Nauck
    Medizinische Klinik 1, St Josef Hospital, Klinikum der Ruhr Universitat Bochum, Gudrunstr 56, D 44791 Bochum, Germany
    Regul Pept 118:89-97. 2004
    ....
  10. ncbi request reprint Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes
    M A Nauck
    Diabeteszentrum, Bad Lauterberg im Harz, Germany
    Exp Clin Endocrinol Diabetes 114:417-23. 2006
    ..Effects of the long acting GLP-1 analogue--liraglutide in subjects with type 2 diabetes...
  11. ncbi request reprint [Therapy with oral antidiabetic agents -- special considerations in the case of coronary heart disease]
    M A Nauck
    Diabeteszentrum Bad Lauterberg
    Dtsch Med Wochenschr 130:1091-6. 2005
  12. ncbi request reprint The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1
    M A Nauck
    Diabeteszentrum Bad Lauterberg, Kirchberg 21, 37431, Bad Lauterberg im Harz, Germany
    Diabetologia 48:608-11. 2005
  13. ncbi request reprint Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes
    Michael A Nauck
    Diabeteszentrum Bad Lauterberg, Kirchberg 21, D 37431 Bad Lauterberg im Harz
    Diabetes 53:S190-6. 2004
    ..On the other hand, this provides a basis to use incretin hormones, especially GLP-1 and its derivatives, to replace a deficiency in incretin-mediated insulin secretion in the treatment of type 2 diabetes...
  14. ncbi request reprint Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers
    Michael A Nauck
    Medizinische Universitäts Klinik, Knappschafts Krankenhaus Bochum, Klinikum der Ruhr Universitat Bochum, D 44892 Bochum, Germany
    J Clin Endocrinol Metab 87:1239-46. 2002
    ..Below plasma glucose concentrations of 4.3 mmol/liter, the insulinotropic action of GLP-1 is negligible...
  15. ncbi request reprint Incretins and their analogues as new antidiabetic drugs
    Michael A Nauck
    Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany
    Drug News Perspect 16:413-22. 2003
    ..GLP-1 derivatives (receptor agonists) with prolonged pharmacokinetics that promise a potential for clinical use in the near future are being developed...
  16. doi request reprint Unraveling the science of incretin biology
    Michael A Nauck
    Bad Lauterberg Diabetes Center, Bad Lauterberg, Germany
    Eur J Intern Med 20:S303-8. 2009
    ..g., weight gain, loss of beta-cell function) associated with type 2 diabetes...
  17. ncbi request reprint The enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms
    M A Nauck
    Diabeteszentrum Bad Lauterberg, Kirchberg 21, D 37431, Bad Lauterberg, Harz, Germany
    Diabetologia 50:2413-6. 2007
  18. doi request reprint Unraveling the science of incretin biology
    Michael A Nauck
    Bad Lauterberg Diabetes Center, Bad Lauterberg, Germany
    Am J Med 122:S3-S10. 2009
    ..g., weight gain, loss of beta-cell function) associated with type 2 diabetes...
  19. doi request reprint Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?
    M Nauck
    Diabeteszentrum Bad Lauterberg, Kirchberg 21, D 37431 Bad Lauterberg im Harz, Germany
    Best Pract Res Clin Endocrinol Metab 23:513-23. 2009
    ..The present manuscript tries to describe the current state-of-the-art of using incretin mimetics and DPP-4 inhibitors in clinical practice, including an attempt to suggest their place in treatment algorithms for type 2-diabetic patients...
  20. doi request reprint Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
    M A Nauck
    Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany
    Diabetologia 54:10-8. 2011
    ..Rather, factors are identified that may determine individual incretin secretory responses and explain some of the variations in published findings of group differences in GLP-1 responses to nutrient intake...
  21. pmc Self-monitoring of blood glucose in diabetes mellitus: arguments for an individualized approach
    Michael A Nauck
    Diabeteszentrum Bad Lauterberg, 37431 Bad Lauterberg, Germany
    Dtsch Arztebl Int 106:587-94. 2009
    ..In this analysis, the authors aim to develop individualized recommendations based on clinical needs and the available literature...
  22. ncbi request reprint Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial
    M A Nauck
    Diabeteszentrum Bad Lauterberg im Harz, Bad Lauterberg, Germany
    Diabetes Obes Metab 9:194-205. 2007
    ..To compare the efficacy and safety of sitagliptin vs. glipizide in patients with type 2 diabetes and inadequate glycaemic control [haemoglobin A(1c) (HbA(1c)) > or = 6.5 and < or = 10%] on metformin monotherapy...
  23. ncbi request reprint Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects
    J J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University Bochum, Gudrunstr 56, 44791, Bochum, Germany
    Diabetologia 50:806-13. 2007
    ..secretion different after oral and during intravenous glucose administration? (2) If so, is this related to the secretion of incretin hormones? (3) Is glucagon secretion abnormal in first-degree relatives of patients with type 2 diabetes?..
  24. doi request reprint Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
    M A Nauck
    Diabeteszentrum Bad Lauterberg im Harz, Bad Lauterberg, Germany
    Int J Clin Pract 63:46-55. 2009
    ..5 and 25 mg in combination with metformin in patients whose HbA(1c) levels were inadequately controlled on metformin alone...
  25. ncbi request reprint A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study
    M A Nauck
    Diabetes Center, Kirchberg 21, 37431, Bad Lauterberg im Harz, Germany
    Diabetologia 50:259-67. 2007
    ..The aim of this 52-week, open-label, non-inferiority trial was to compare the safety and efficacy of exenatide (an incretin mimetic) with that of biphasic insulin aspart...
  26. doi request reprint Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study
    M Nauck
    Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Bad Lauterberg, Germany
    Diabetes Obes Metab 15:204-12. 2013
    ..To investigate efficacy and safety of dual therapy with liraglutide and metformin in comparison to glimepiride and metformin, and metformin monotherapy over 2 years in patients with type 2 diabetes...
  27. ncbi request reprint A 25-year follow-up study of glucose tolerance in first-degree relatives of type 2 diabetic patients: association of impaired or diabetic glucose tolerance with other components of the metabolic syndrome
    M A Nauck
    Diabetes Center Bad Lauterberg, Kirchberg 21, D 37431 Bad Lauterberg in Harz, Germany
    Acta Diabetol 40:163-72. 2003
    ..A metabolic syndrome should certainly be diagnosed if three components are present, although even in the presence of only two components, an elevated risk is evident...
  28. pmc Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?
    J J Meier
    Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany
    Heart 90:9-12. 2004
    ..Myocardial ischaemia can also develop during emergency or elective angioplasty and during coronary bypass surgery. Therefore discontinuation of sulfonylurea treatment should be considered in these circumstances...
  29. ncbi request reprint Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers
    S Meier
    Medizinische Universitäts Klinik, Knappschafts Krankenhaus Bochum, Klinikum der Ruhr Universitat Bochum, Germany
    Horm Metab Res 35:551-6. 2003
    ..Memory effects exist for glucose and sulfonylureas. It is not known whether there is a B-cell memory for incretin hormones such as GLP-1...
  30. ncbi request reprint Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia
    J J Meier
    Medizinische Klinik I, St Josef Hospital, Klinikum der Ruhr Universitat Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    Diabetologia 46:798-801. 2003
    ..Therefore, we studied the effect of GIP on glucagon secretion under normoglycaemic conditions...
  31. doi request reprint Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial
    M Nauck
    Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany
    Diabet Med 30:109-13. 2013
    ..To compare the efficacy and safety of once-weekly taspoglutide with insulin glargine in patients with advanced Type 2 diabetes failing metformin and sulphonylurea combination therapy...
  32. ncbi request reprint Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes
    J J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University of Bochum, Bochum, Germany
    Diabetologia 48:1872-81. 2005
    ..The secretion of GIP and GLP-1 was assessed following oral glucose ingestion...
  33. doi request reprint Excess glycaemic excursions after an oral glucose tolerance test compared with a mixed meal challenge and self-measured home glucose profiles: is the OGTT a valid predictor of postprandial hyperglycaemia and vice versa?
    J J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University Bochum, Bochum, Germany
    Diabetes Obes Metab 11:213-22. 2009
    ..We addressed whether (i) glucose concentrations after an oral glucose load are similar to those after a test meal or under daily life conditions and (ii) impaired glucose tolerance (IGT) predicts postprandial hyperglycaemia...
  34. doi request reprint Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes
    Irfan Vardarli
    Diabeteszentrum Bad Lauterberg, 37431 Bad Lauterberg, Germany
    J Clin Endocrinol Metab 96:945-54. 2011
    ..The aim of the present study was to quantitatively assess the incretin effect after treatment with the DPP-4 inhibitor vildagliptin (V) or placebo (P) in patients with type 2 diabetes...
  35. ncbi request reprint Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans
    J J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University, Bochum, Germany
    Diabetologia 49:452-8. 2006
    ..Exogenous glucagon-like peptide 1 (GLP-1) lowers postprandial glycaemia predominantly by slowing gastric emptying. Therefore, the effects of GLP-1 on postprandial lipid levels and gastric emptying were assessed...
  36. ncbi request reprint The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion
    Andrea El-Ouaghlidi
    Diabeteszentrum Bad Lauterberg, Kirchberg 21, D 37431 Bad Lauterberg im Harz, Germany
    J Clin Endocrinol Metab 92:4165-71. 2007
    ..The present study asked whether vildagliptin accentuates glibenclamide-induced hypoglycemia or affects endogenous secretion of GLP-1 and GIP after an oral glucose tolerance test...
  37. ncbi request reprint Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans
    Juris J Meier
    Department of Medicine I, St Josef Hospital, Ruhr Univ of Bochum, Gudrunstr 56, 44791 Bochum, Germany
    Am J Physiol Endocrinol Metab 293:E849-56. 2007
    ..An inverse relationship between insulin concentrations and insulin clearance suggests that the secretion of insulin itself determines the rate of hepatic insulin clearance...
  38. ncbi request reprint Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects
    Juris J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University Bochum, Germany
    Metabolism 52:1579-85. 2003
    ..Therefore, a reduced GIP-induced insulin secretion in patients with type 2 diabetes and their first-degree relatives at hyperglycemia is more likely due to a general defect of B-cell function than to a specific defect of the GIP action...
  39. ncbi request reprint Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance
    Kirsten Vollmer
    Department of Medicine I, St Josef Hospital, Ruhr University Bochum, Gudrunstr 56, 44791 Bochum, Germany
    Diabetes 57:678-87. 2008
    ..in GLP-1 levels different after mixed meal or isolated glucose ingestion? 2) Which endogenous factors are associated with the concentrations of GLP-1? In particular, do elevated fasting glucose or glucagon levels diminish GLP-1 responses?..
  40. doi request reprint Comparison of pancreas-transplanted type 1 diabetic patients with portal-venous versus systemic-venous graft drainage: impact on glucose regulatory hormones and the growth hormone/insulin-like growth factor-I axis
    Jan Frystyk
    Medical Research Laboratories, Aarhus University Hospital, Nørrebrogade 44, Aarhus C, Denmark
    J Clin Endocrinol Metab 93:1758-66. 2008
    ..Pancreas grafts can be drained through the iliac vein (systemic drainage) or the portal vein...
  41. doi request reprint Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?
    Luc F Van Gaal
    Department of Diabetology, Metabolism and Clinical Nutrition, Antwerp University Hospital, Wilrijkstraat 10 B 2650 Edegem, Antwerp, Belgium
    Eur J Endocrinol 158:773-84. 2008
    ....
  42. ncbi request reprint Gastric inhibitory polypeptide: the neglected incretin revisited
    Juris J Meier
    Medizinische Klinik I, St Josef Hospital, Klinikum der Ruhr Universitat Bochum, Gudrunstrasse 56, 44791, Bochum, Germany
    Regul Pept 107:1-13. 2002
    ..The present work aims to review the physiological functions of GIP, to characterize its role in the pathogenesis of type 2 diabetes, and to discuss possible clinical applications and future perspectives in the light of new findings...
  43. ncbi request reprint Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes
    Frauke Fehse
    Diabeteszentrum Bad Lauterberg, Kirchberg 21, D 37431 Bad Lauterberg im Harz, Germany
    J Clin Endocrinol Metab 90:5991-7. 2005
    ..The incretin mimetic exenatide has glucoregulatory activities in DM2, including glucose-dependent enhancement of insulin secretion...
  44. ncbi request reprint The reduction in hepatic insulin clearance after oral glucose is not mediated by gastric inhibitory polypeptide (GIP)
    Juris J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University Bochum, Germany
    Regul Pept 113:95-100. 2003
    ..0001), but not the intravenous GIP administration (p=0.18) significantly reduced insulin clearance. Therefore, insulin clearance is reduced after an oral glucose load. This effect does not appear to be mediated by GIP...
  45. ncbi request reprint Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus
    Juris J Meier
    Medizinische Klinik I, St Josef Hospital, Klinikum der Ruhr Universitat Bochum, Bochum, Germany
    BioDrugs 17:93-102. 2003
    ..Numerous clinical studies are currently underway to evaluate these approaches. Therefore, an antidiabetic treatment based on incretin hormones may become available within the next 5 years...
  46. ncbi request reprint Gastric inhibitory polypeptide does not inhibit gastric emptying in humans
    Juris J Meier
    Division of Endocrinology and Diabetes, Keck School of Medicine, University of Southern California, 1333 San Pablo St, BMT BII, Los Angeles, CA 90033, USA
    Am J Physiol Endocrinol Metab 286:E621-5. 2004
    ..The secretion of GIP after meal ingestion is not suppressed by its exogenous administration. The lack of effect of GIP on gastric emptying underlines the differences between GIP and the second incretin glucagon-like peptide 1...
  47. ncbi request reprint Glucagon-like peptide 1(GLP-1) in biology and pathology
    Juris J Meier
    Larry L Hillblom Islet Research Center, UCLA School of Medicine, Los Angeles, USA
    Diabetes Metab Res Rev 21:91-117. 2005
    ..This review will summarize the biological effects of GLP-1, characterize its role in human biology and pathology, and discuss potential clinical applications as well as current clinical studies...
  48. ncbi request reprint Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide
    Juris J Meier
    Larry Hillblom Islet Research Center, UCLA School of Medicine, Los Angeles, CA, USA
    Best Pract Res Clin Endocrinol Metab 18:587-606. 2004
    ..This review will summarize the actions of GIP in human physiology and discuss its role in the pathogenesis of type 2 diabetes, as well as the therapeutic options derived from these findings...
  49. ncbi request reprint Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes
    Michael A Nauck
    Medizinische Klinik 1, St Josef Hospital, Ruhr Universitat Bochum, Bochum D 44791, Germany
    Regul Pept 122:209-17. 2004
    ....
  50. ncbi request reprint The potential role of glucagon-like peptide 1 in diabetes
    Juris J Meier
    Larry Hillblom Islet Research Center, UCLA David Geffen School of Medicine, 24 130 Warren Hill, 900 Veteran Avenue, Los Angeles, CA 90095, USA
    Curr Opin Investig Drugs 5:402-10. 2004
    ..The physiological effects of GLP-1 and its pharmacokinetic limitations will be reviewed here, and the current therapeutic approaches based on GLP-1 discussed...
  51. ncbi request reprint Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects
    Juris J Meier
    Department of Medicine, Ruhr University, Bochum, Germany
    Diabetes 54:2212-8. 2005
    ....
  52. ncbi request reprint Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes
    Juris J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University Bochum, Germany
    Crit Care Med 32:848-51. 2004
    ..Therefore, the glucose-lowering effect of the incretin hormone glucagon-like peptide 1 (GLP-1) was investigated in patients with type 2 diabetes after major surgery...
  53. ncbi request reprint Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans
    Juris J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University, Bochum, Germany
    Gastroenterology 130:44-54. 2006
    ..However, the acute effects of GLP-2 on gastric functions as well as on glucose and lipid homeostasis in humans are less well characterized...
  54. ncbi request reprint The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans
    Juris J Meier
    Dept of Medicine I, St Josef Hospital, Ruhr Univ Bochum, Gudrunstr 56, 44791 Bochum, Germany
    Am J Physiol Endocrinol Metab 290:E1118-23. 2006
    ..Most likely, this is because of direct effects on glucose disposal. However, the glucose-lowering potential of GLP-1-(9-36) amide appears to be small compared with that of intact GLP-1-(7-36) amide...
  55. ncbi request reprint Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses
    Tanya J Little
    Department of Medicine, University of Adelaide, Royal Adelaide Hospital, Adelaide, South Australia 5000, Australia
    J Clin Endocrinol Metab 91:1916-23. 2006
    ..The inhibitory action of glucagon-like peptide-1 (GLP-1) on gastric emptying (GE) is likely to be important in mediating its effects on postprandial glycemia, appetite, and gastrointestinal symptoms...
  56. ncbi request reprint Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes
    Juris J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University, 44791 Bochum, Germany
    J Clin Endocrinol Metab 88:2719-25. 2003
    ..4 pmol GLP-1/kg x min. Due to the dose-dependent inhibition of gastric emptying, lower GLP-1 doses than previously used may be as suitable for glucose control in patients with type 2 diabetes...
  57. ncbi request reprint The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
    Daniel J Drucker
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    Lancet 368:1696-705. 2006
    ..However, long-term clinical studies are needed to determine the benefits of targeting the incretin axis for the treatment of type 2 diabetes...
  58. ncbi request reprint Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects
    Juris J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University Bochum, Bochum, Germany
    Diabetes 53:654-62. 2004
    ..Delayed elimination of GLP-1 and GIP in renal insufficiency may influence the pharmacokinetics and pharmacodynamics of dipeptidyl peptidase IV-resistant incretin derivatives to be used for the treatment of patients with type 2 diabetes...
  59. ncbi request reprint Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives
    Juris J Meier
    Medizinische Klinik I, St Josef Hospital, Klinikum der Ruhr Universitat Bochum, Gudrunstr 56, Germany
    Eur J Pharmacol 440:269-79. 2002
    ..The present review aims to describe the role of GLP-1 in the central regulation of feeding and to discuss its possible application in the pharmacotherapy of obesity...
  60. ncbi request reprint Plasma glucose at hospital admission and previous metabolic control determine myocardial infarct size and survival in patients with and without type 2 diabetes: the Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBD
    Juris J Meier
    Department of Medicine, Ruhr University, Knappschafts Krankenhaus, Bochum, Germany
    Diabetes Care 28:2551-3. 2005
  61. ncbi request reprint Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
    Juris J Meier
    Lancet 360:257. 2002